Answers are grounded in this paper and cite their sources.
Introduction In our previous study, 97% overall survival (OS) rate was obtained with an intense regimen for adjuvant therapy for patients with International Retinoblastoma Staging System (IRSS) stage I unilateral retinoblastoma and high-risk pathology (HRP), but toxicity was high. We designed this study to assess the results of a reduced-intensity and duration adjuvant therapy for stages I-II and to evaluate the results of intra-arterial chemotherapy (IAC) for Stage 0. Methods Single-arm, prospective study. Eligible patients included IRSS stage 0-II unilateral retinoblastoma from 2018 to 2023. For stage I, patients with HRP (defined as postlaminar optic nerve and or/scleral invasion) received adjuvant therapy with 6 cycles of a reduced-dose chemotherapy including carboplatin, etoposide alternating with cyclophosphamide, idarubicin and vincristine plus intrathecal topotecan. Stage II patients received 8 cycles of an intensified regimen plus intrathecal topotecan and orbital radiotherapy only for those with tumor at the resection margin of the optic nerve. Patients with Stage 0 received IAC and intravitreal chemotherapy for vitreous seeding. Main outcome measures were 3-year OS for all stages and 3-year ocular survival for Stage 0. Results The protocol was designed as a multi-institutional study but it could be opened in one center. Eighty-four patients were enrolled (median follow-up of 45.6 months). The 3-year OS for the entire cohort was 98.7% (100% for stage 0 and I. 3/4 patients with stage II survived). No events occurred in 42 enucleated patients who did not receive adjuvant therapy or the group with HRP (n=20). Among the 18 patients with stage 0, the 3-year ocular survival rate was 71.7%. Events included one fatal CNS relapse in a patient with stage II and a subsequent malignancy in the group of stage 0. The reduced-dose regimen had a significantly lower number of transfusions (p=0.002 for blood cells and 0.02 for platelets). Intrathecal topotecan caused occasional grade I-II toxicity. Conclusions High survival outcomes were achieved. Compared to the previous protocol, hematological toxicity was reduced, and there were no toxic deaths or severe adverse events associated with intrathecal topotecan. Treatment of stage 0 patients with IAC resulted in high ocular preservation rates. Clinical trial registration https://clinicaltrials.gov/study/NCT03475121?cond=retinoblastoma&term=GALOP&rank=1 , identifier NCT03475121.
No takes yet. Share an insight, caveat, or question.
Sampor et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: